HealthEquity Financial Statements (HQY)
|
|
|
|
Report date
|
|
|
31.03.2022 |
31.01.2023 |
30.03.2023 |
31.01.2024 |
22.03.2024 |
|
03.09.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
756.6 |
861.7 |
861.7 |
999.6 |
999.6 |
|
1 112 |
|
Operating Income, bln rub |
|
|
34.6 |
9.06 |
38.9 |
128.1 |
128.1 |
|
186.8 |
|
EBITDA, bln rub |
? |
|
103.0 |
171.5 |
171.5 |
281.2 |
282.4 |
|
350.0 |
|
Net profit, bln rub |
? |
|
-44.3 |
-50.0 |
-26.1 |
55.7 |
55.7 |
|
117.4 |
|
|
OCF, bln rub |
? |
|
141.0 |
150.7 |
150.7 |
242.8 |
242.8 |
|
327.7 |
|
CAPEX, bln rub |
? |
|
137.1 |
48.5 |
119.1 |
42.8 |
46.1 |
|
498.3 |
|
FCF, bln rub |
? |
|
3.91 |
102.1 |
31.5 |
200.0 |
196.8 |
|
-170.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
383.1 |
481.0 |
452.4 |
401.7 |
401.7 |
|
428.1 |
|
Cost of production, bln rub |
|
|
332.9 |
371.7 |
371.7 |
469.7 |
377.0 |
|
497.4 |
|
R&D, bln rub |
|
|
157.4 |
193.4 |
193.4 |
218.8 |
218.8 |
|
225.1 |
|
Interest expenses, bln rub |
|
|
36.6 |
48.4 |
48.4 |
55.5 |
55.5 |
|
54.5 |
|
|
Assets, bln rub |
|
|
3 107 |
3 089 |
3 089 |
3 164 |
3 164 |
|
3 514 |
|
Net Assets, bln rub |
? |
|
1 853 |
1 896 |
1 896 |
2 035 |
2 035 |
|
2 157 |
|
Debt, bln rub |
|
|
1 008 |
994.5 |
994.5 |
933.1 |
933.1 |
|
1 157 |
|
Cash, bln rub |
|
|
225.4 |
254.3 |
254.3 |
404.0 |
404.0 |
|
326.9 |
|
Net debt, bln rub |
|
|
782.8 |
740.2 |
740.2 |
529.2 |
529.2 |
|
830.6 |
|
|
Ordinary share price, rub |
|
|
53.4 |
60.9 |
60.9 |
75.6 |
75.6 |
|
66.2 |
|
Number of ordinary shares, mln |
|
|
83.1 |
84.4 |
84.4 |
85.6 |
85.6 |
|
87.1 |
|
|
Market cap, bln rub |
|
|
4 443 |
5 138 |
5 138 |
6 467 |
6 467 |
|
5 769 |
|
EV, bln rub |
? |
|
5 225 |
5 879 |
5 879 |
6 996 |
6 996 |
|
6 600 |
|
Book value, bln rub |
|
|
-766 |
-689 |
-689 |
387 |
-449 |
|
-745 |
|
|
EPS, rub |
? |
|
-0.53 |
-0.59 |
-0.31 |
0.65 |
0.65 |
|
1.35 |
|
FCF/share, rub |
|
|
0.05 |
1.21 |
0.37 |
2.34 |
2.30 |
|
-1.96 |
|
BV/share, rub |
|
|
-9.22 |
-8.16 |
-8.16 |
4.52 |
-5.25 |
|
-8.55 |
|
|
EBITDA margin, % |
? |
|
13.6% |
19.9% |
19.9% |
28.1% |
28.3% |
|
31.5% |
|
Net margin, % |
? |
|
-5.85% |
-5.81% |
-3.03% |
5.57% |
5.57% |
|
10.6% |
|
FCF yield, % |
? |
|
0.09% |
1.99% |
0.61% |
3.09% |
3.04% |
|
-2.96% |
|
ROE, % |
? |
|
-2.39% |
-2.64% |
-1.38% |
2.74% |
2.74% |
|
5.44% |
|
ROA, % |
? |
|
-1.43% |
-1.62% |
-0.85% |
1.76% |
1.76% |
|
3.34% |
|
|
P/E |
? |
|
-100.3 |
-102.7 |
-196.5 |
116.1 |
116.1 |
|
49.2 |
|
P/FCF |
|
|
1 135 |
50.3 |
163.0 |
32.3 |
32.9 |
|
-33.8 |
|
P/S |
? |
|
5.87 |
5.96 |
5.96 |
6.47 |
6.47 |
|
5.19 |
|
P/BV |
? |
|
-5.80 |
-7.46 |
-7.46 |
16.7 |
-14.4 |
|
-7.74 |
|
EV/EBITDA |
? |
|
50.7 |
34.3 |
34.3 |
24.9 |
24.8 |
|
18.9 |
|
Debt/EBITDA |
|
|
7.60 |
4.32 |
4.32 |
1.88 |
1.87 |
|
2.37 |
|
|
R&D/CAPEX, % |
|
|
114.8% |
398.3% |
162.3% |
511.0% |
474.9% |
|
45.2% |
|
|
CAPEX/Revenue, % |
|
|
18.1% |
5.63% |
13.8% |
4.28% |
4.61% |
|
44.8% |
|
| HealthEquity shareholders |
